Incidence of electrocardiographic abnormalities during treatment with human leukocyte interferon-alfa in patients with chronic hepatitis C but without preexisting cardiovascular disease

Current Therapeutic Research - Clinical and Experimental

Volumn 59, Issue 10, 1998, Pages 692-696

  Colivicchi, Furio ^a,b   Magnanimi, Stefania ^a   Sebastiani, Franco ^a   Silvestri, Roberto ^a   Magnanimi, Roberto ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Adverse reaction; Chronic hepatitis C; Electrocardiography; Human leukocyte interferon alfa; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; CONVALESCENCE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT BUNDLE BRANCH BLOCK; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE;

EID: 0031762783     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(98)85027-3     Document Type: Article

References (13)

1. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic type C hepatitis with alpha interferon. Semin Liver Dis. 1989;9:259-263.
2. Hoofnagle JH. Interferon therapy of viral hepatitis. In: Baron S, Coppenhaver DH, Dianzani F, et al, eds. Interferon. Principles and Clinical Applications. Galveston, Tex: University of Texas Medical Branch of Galveston; 1992:433-462.
3. Sonnenblik M, Rosin A. Cardiotoxicity of interferon: A review of 44 cases. Chest. 1991;99:557-561.
4. Samsonov MY, Nassonov EL, Wacther H, Fuchs D. Heart disease and immune system activation. Eur J Intern Med. 1993;4:267-274.
5. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115-150.
6. Teragawa H, Hondo T, Amano H, et al. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996;37:905-915.
7. Colivicchi F, Magnanimi S, Sebastiani F, et al. Cardiac arrhythmias and intraventricular conduction defects during treatment with human leukocyte alpha interferon in patients affected by chronic hepatitis C. Hepatol Rap Lit Rev. 1994;24:IX-X.
8. Sartori M, Andorno S, La Terra G, et al. Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur J Clin Invest. 1995;25:68-70.
9. Fisch C. Electrocardiography and vectocardiography. In: Braunwald E, ed. Heart Disease. 4th ed. Philadelphia: WB Saunders; 1992:117-160.
10. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med. 1988;85:549-551.
11. Tester-Dalderup CBM. Drugs acting on the immune system. In: Dukes MNG, ed. Meyler's Side Effects of Drugs. An Encyclopedia of Adverse Reactions and Interactions. 13th ed. Amsterdam: Elsevier; 1996:1090-1168.
12. Schechter D, Nager A. Recombinant interleukin-2 and recombinant interferon alpha immunotherapy cardiovascular toxicity. Am Heart J. 1992;123:1736-1739.
13. Chou TC. Electrocardiography in Clinical Practice. 3rd ed. Philadelphia: WB Saunders; 1991.